Ocular novel drug delivery: impacts of membranes and barriers
The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Ocular drug delivery is an extremely challenging area due to its restrictive barrier functionalities. OBJECTIVE: Drug transport via corneal/non-corneal routes involves several intricate biological processes such as drug penetration across the ocular barriers and transfer to the anterior or posterior chambers, thus the influence of these processes on the pharmacotherapy of the eye should be fully addressed. METHODS: To pursue the impacts of such impediments in novel drug therapy, recent publications were reviewed regarding advanced strategies such as nanomedicines. CONCLUSION: The ocular barriers are highly specialized and selectively control the inward/outward traverse of compounds, hence a better understanding of these biological obstacles would provide a platform to advance ophthalmic drug therapy towards specified delivery/targeting with minimal adverse consequences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Challenges and obstacles of ocular pharmacokinetics and drug delivery
Urtti, A. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.07.027 · Cited by 1,003
The use of mucoadhesive polymers in ocular drug delivery
LUDWIG, A. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.07.005 · Cited by 922
Nanotechnology in ocular drug delivery
Sahoo, S. K., Dilnawaz, F., & Krishnakumar, S. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.10.021 · Cited by 510
Vesicular systems in ocular drug delivery: an overview
Kaur, I. P., Garg, A., Singla, A. K., & Aggarwal, D. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2003.09.016 · Cited by 450
Corneal Penetration Behavior of β-Blocking Agents I: Physicochemical Factors
Huang, H.-S., & Schoenwald, R. D. (1983) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600721108 · Cited by 422
Nanotechnology in Ocular Drug Delivery
Patel, D., Pathak, D., & Giradkar, P. (2021) · Nanocarriers: Drug Delivery System · doi:10.1007/978-981-33-4497-6_18 · Cited by 362
(2000) · PubMed · Cited by 358
Mannermaa, E., Vellonen, K.-S., & Urtti, A. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.07.024 · Cited by 349
Ghate, D., & Edelhauser, H. F. (2006) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.3.2.275 · Cited by 329
Nanomedicines for overcoming biological barriers
José Alonso, M. (2004) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2004.01.007 · Cited by 312
Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1
Shen, J., Samul, R., Silva, R. L., Akiyama, H., Liu, H., Saishin, Y., Hackett, S. F., Zinnen, S., Kossen, K., Fosnaugh, K., et al. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302641 · Cited by 307
Cell culture models of the ocular barriers
Hornof, M., Toropainen, E., & Urtti, A. (2005) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2005.01.009 · Cited by 300
Cao, Y., Zhang, C., Shen, W., Cheng, Z., Yu, L. (., & Ping, Q. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.05.009 · Cited by 299
Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera.
Hämäläinen, K. M., Kananen, K., Auriola, S. O. K., Kontturi, K., & Urtti, A. O. (1997) · PubMed · Cited by 266
Periocular routes for retinal drug delivery
Raghava, S., Hammond, M., & Kompella, U. B. (2004) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.1.1.99 · Cited by 257 · cited 1×
“The intravitreal route appears to be the major route of drug administration to the posterior segment, in which the diffusivity potential of the vitreous depends on the pathophysiological state and molecular weight of the administered drugs [2,56] .”
BackgroundDrug delivery to the retina: challenges and opportunities
Duvvuri, S., Majumdar, S., & Mitra, A. K. (2003) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.3.1.45 · Cited by 249
Omidi, Y., Campbell, L., Barar, J., Connell, D., Akhtar, S., & Gumbleton, M. (2003) · Brain Research · doi:10.1016/s0006-8993(03)03443-7 · Cited by 246
Self-citationNovel approaches to retinal drug delivery
Janoria, K. G., Gunda, S., Boddu, S. H., & Mitra, A. K. (2007) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.4.4.371 · Cited by 213
Biodegradable microspheres for vitreoretinal drug delivery
Herrero-Vanrell, R., & Refojo, M. F. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00200-9 · Cited by 211
Le Meur, G., Stieger, K., Smith, A. J., Weber, M., Deschamps, J. Y., Nivard, D., Mendes-Madeira, A., Provost, N., Péréon, Y., Cherel, Y., et al. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302861 · Cited by 207
Hosoya, K.-I., Lee, V. H. L., & Kim, K.-J. (2005) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2004.12.007 · Cited by 194
Vitreous: A Barrier to Nonviral Ocular Gene Therapy
Peeters, L., Sanders, N. N., Braeckmans, K., Boussery, K., Van de Voorde, J., De Smedt, S. C., & Demeester, J. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-0165 · Cited by 189
The blood-ocular barriers: past, present, and future
Cunha-vaz, J. G. (1997) · Documenta Ophthalmologica · doi:10.1007/bf02569055 · Cited by 187
Treatment of Cytomegalovirus Retinitis with Intravitreal Ganciclovir
Cantrill, H. L., Henry, K., Melroe, N. H., Knobloch, W. H., Ramsay, R. C., & Balfour, H. H. (1989) · Ophthalmology · doi:10.1016/s0161-6420(89)32900-9 · Cited by 185
Rheology of the vitreous body. Part I: Viscoelasticity of human vitreous
Lee, B., Litt, M., & Buchsbaum, G. (1992) · Biorheology · doi:10.3233/bir-1992-295-612 · Cited by 179
Corneal Penetration Behavior of β-Blocking Agents II: Assessment of Barrier Contributions
Lach, J. L., Huang, H.-S., & Schoenwald, R. D. (1983) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600721109 · Cited by 176
Nanoparticles for gene delivery to retinal pigment epithelial cells.
Bejjani, R. A., BenEzra, D., Cohen, H., Rieger, J., Andrieu‐Soler, C., Jeanny, J., Gollomb, G., & Béhar‐Cohen, F. (2005) · PubMed · Cited by 176
Transport Barriers in Transscleral Drug Delivery for Retinal Diseases
Kim, S. H., Lutz, R. J., Wang, N. S., & Robinson, M. R. (2007) · Ophthalmic Research · doi:10.1159/000108117 · Cited by 172
Adibkia, K., Shadbad, M. R. S., Nokhodchi, A., Javadzedeh, A., Barzegar-Jalali, M., Barar, J., Mohammadi, G., & Omidi, Y. (2007) · Journal of drug targeting · doi:10.1080/10611860701453125 · Cited by 165
Self-citationGene therapy progress and prospects: the eye
Bainbridge, J. W., Tan, M. H., & Ali, R. R. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302812 · Cited by 162
Qaddoumi, M. G., Gukasyan, H. J., Davda, J. P., Labhasetwar, V. D., Kim, K. J., & Lee, V. H. L. (2003) · PubMed · Cited by 157
Ion transport mechanisms in native human retinal pigment epithelium.
Quinn, R. H., & Miller, S. S. (1992) · PubMed · Cited by 142
Robinson, M. R., Lee, S. S., Kim, H., Kim, S., Lutz, R. J., Galbán, C. J., Bungay, P. M., Yuan, P., Wang, N. S., Kim, J., et al. (2005) · Experimental Eye Research · doi:10.1016/j.exer.2005.08.007 · Cited by 142
Boado, R. J., Zhang, Y., Zhang, Y., Xia, C., Wang, Y., & Pardridge, W. M. (2008) · Biotechnology and Bioengineering · doi:10.1002/bit.21602 · Cited by 142
Lazić, R., & Gabrić, N. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.03.006 · Cited by 140
Molecular mechanisms of water transport in the eye
Hamann, S. (2002) · International review of cytology · doi:10.1016/s0074-7696(02)15016-9 · Cited by 135
Human serum albumin nanoparticles for efficient delivery of Cu, Zn superoxide dismutase gene.
Mo, Y., Barnett, M. E., Takemoto, D. J., Davidson, H. J., & Kompella, U. B. (2007) · PubMed Central · Cited by 133
Dey, S., Patel, J., Anand, B. S., Jain-Vakkalagadda, B., Kaliki, P., Pal, D., Ganapathy, V., & Mitra, A. K. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.02-1142 · Cited by 128
Blood‐eye barriers in the rat: Correlation of ultrastructure with function
Stewart, P. A., & Tuor, U. I. (1994) · Journal of Comparative Neurology · doi:10.1002/cne.903400409 · Cited by 128
Significance of Mucin on the Ocular Surface
Watanabe, H. (2002) · Cornea · doi:10.1097/00003226-200203001-00005 · Cited by 127
Liaw, J., Chang, S.-F., & Hsiao, F.-C. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301485 · Cited by 127
New estimates of drug development costs
Frank, R. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(03)00002-x · Cited by 126
Distribution of monocarboxylate transporters MCT1 and MCT2 in rat retina
Gerhart, D. Z., Leino, R. L., & Drewes, L. R. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00699-x · Cited by 122
Rocha, E. M., Cunha, D. A., Carneiro, E. M., Boschero, A. C., Saad, M. J. A., & Velloso, L. A. (2002) · PubMed · Cited by 115
Ocular Drug Delivery: Nanomedicine Applications
Vandervoort, J., & Ludwig, A. (2007) · Nanomedicine · doi:10.2217/17435889.2.1.11 · Cited by 114
Nanoparticle applications in ocular gene therapy
Cai, X., Conley, S. M., & Naash, M. I. (2007) · Vision Research · doi:10.1016/j.visres.2007.07.012 · Cited by 111
Blood–brain barrier delivery of protein and non-viral gene therapeutics with molecular Trojan horses
Pardridge, W. M. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.04.001 · Cited by 102
Shifting the Paradigm of the Blood–Aqueous Barrier
Freddo, T. F. (2001) · Experimental Eye Research · doi:10.1006/exer.2001.1056 · Cited by 98
The relationship of astrocyte-like cells to the vessels that contribute to the blood-ocular barriers
Holash, J. A., & Stewart, P. A. (1993) · Brain Research · doi:10.1016/0006-8993(93)91323-k · Cited by 95
Non-viral ocular gene therapy: Potential ocular therapeutic avenues
Bloquel, C., Bourges, J., Touchard, E., Berdugo, M., BenEzra, D., & Béhar‐Cohen, F. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.07.023 · Cited by 93
Pharmacological Regulation of Protein Expression from Adeno-Associated Viral Vectors in the Eye
Auricchio, A., Rivera, V. M., Clackson, T., O'Connor, E. E., Maguire, A. M., Tolentino, M. J., Bennett, J., & Wilson, J. M. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0660 · Cited by 91
Bu, H., Gukasyan, H. J., Goulet, L., Lou, X., Xiang, C. D., & Koudriakova, T. B. (2007) · Current Drug Metabolism · doi:10.2174/138920007779815977 · Cited by 91
Chang, J.-E., Basu, S. K., & Lee, V. H. L. (2000) · Pharmaceutical Research · doi:10.1023/a:1007569929765 · Cited by 82
Review: New Directions in the Optimization of Ocular Drug Delivery
Lee, V. H. L. (1990) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.1990.6.157 · Cited by 80
Smith, M., Omidi, Y., & Gumbleton, M. (2007) · Journal of Drug Targeting · doi:10.1080/10611860701288539 · Cited by 77
Self-citationOcular gene therapy: a review of nonviral strategies.
Andrieu‐Soler, C., Bejjani, R. A., de Bizemont, T., Normand, N., BenEzra, D., & Béhar‐Cohen, F. (2006) · PubMed · Cited by 77
Kompella, U. B., Sundaram, S., Raghava, S., & Escobar, E. R. (2006) · PubMed · Cited by 77
The molecular structure and function of the inner blood-retinal barrier
Gardner, T. W., Antonetti, D. A., Barber, A. J., Lieth, E., & Tarbell, J. A. (1999) · Documenta Ophthalmologica · doi:10.1023/a:1002140812979 · Cited by 74
Existence of a p-glycoprotein drug efflux pump in cultured rabbit conjunctival epithelial cells.
Saha, P., Yang, J. J., & Lee, V. H. L. (1998) · PubMed · Cited by 73
A primary culture model of rabbit conjunctival epithelial cells exhibiting tight barrier properties
Saha, P., Kim, K.-J., & Lee, V. H. L. (1996) · Current Eye Research · doi:10.3109/02713689608995151 · Cited by 73
Amino Acid Transporter ATB0,+ as a Delivery System for Drugs and Prodrugs
Ganapathy, M. E., & Ganapathy, V. (2005) · Current Drug Targets - Immune Endocrine & Metabolic Disorders · doi:10.2174/156800805774912953 · Cited by 73
The Noncorneal Route in Ocular Drug Delivery
Ahmed, I. (2003) · CRC Press eBooks · doi:10.1201/9780203912072-15 · Cited by 65
Sanders, N. N., Peeters, L., Lentacker, I., Demeester, J., & Smedt, S. C. D. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.05.004 · Cited by 63
Expression and localization of Na+-HCO3 − cotransporter in bovine corneal endothelium
Sun, X. C., Bonanno, J. A., Jelamskii, S., et al. (2000) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2000.279.5.c1648 · Cited by 61
López-Cortés, L. F., Pastor-Ramos, M. T., Ruiz-Valderas, R., Cordero, E., Uceda‐Montañés, A., Claro, C., & Lucero, M. J. (2001) · PubMed · Cited by 59
Karla, P. K., Pal, D., Quinn, T., & Mitra, A. K. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.11.031 · Cited by 59
Pseudotyped AAV vectors for constitutive and regulated gene expression in the eye
Auricchio, A. (2003) · Vision Research · doi:10.1016/s0042-6989(02)00676-4 · Cited by 57
Transporters and receptors in ocular drug delivery: opportunities and challenges
Dey, S., & Mitra, A. K. (2005) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2.2.201 · Cited by 56
Mitra, A. K., Anand, B. S., & Duvvuri, S. (2005) · Advances in organ biology · doi:10.1016/s1569-2590(05)10012-3 · Cited by 53
Hunt, R. C., Dewey, A. R., & Davis, A. A. (1989) · Journal of Cell Science · doi:10.1242/jcs.92.4.655 · Cited by 53
Ciliary Muscle Capillaries Have Blood–Tissue Barrier Characteristics
Schlingemann, R. O., Hofman, P., KLOOSTER, J., Blaauwgeers, H. G. T., van der Gaag, R., & Vrensen, G. F. J. M. (1998) · Experimental Eye Research · doi:10.1006/exer.1998.0483 · Cited by 45
Effect of P-glycoprotein on the ocular disposition of a model substrate, quinidine
Duvvuri, S., Gandhi, M. D., & Mitra, A. K. (2003) · Current Eye Research · doi:10.1076/ceyr.27.6.345.18187 · Cited by 45
Omidi, Y., Barar, J., Ahmadian, S., Heidari, H. R., & Gumbleton, M. (2008) · Cell Biochemistry and Function · doi:10.1002/cbf.1455 · Cited by 45
Self-citationCorneal Penetration Behavior of β-Blocking Agents III: In Vitro–In Vivo Correlations
Lach, J. L., Huang, H.-S., & Schoenwald, R. D. (1983) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600721110 · Cited by 44
Na-dependent pHi regulatory mechanisms in native human retinal pigment epithelium.
Lin, H., Kenyon, E., & Miller, S. S. (1992) · PubMed · Cited by 34
Ma, L., Kuang, K., Smith, R. W., Rittenband, D., Iserovich, P., DIECKE, F. P. J., & Fischbarg, J. (2007) · Experimental Eye Research · doi:10.1016/j.exer.2006.12.018 · Cited by 34
D‐TAT transporter as an ocular peptide delivery system
Schorderet, D. F., Manzi, V. D., Canola, K., Bonny, C., Arsenijévic, Y., Munier, F. L., & Maurer, F. (2005) · Clinical and Experimental Ophthalmology · doi:10.1111/j.1442-9071.2005.01108.x · Cited by 33
Jentsch, T. J., Matthes, H., Keller, S. K., & Wiederholt, M. (1985) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/bf00584097 · Cited by 32
Membrane Transport Processes in the Eye
Sunkara, G., & Kompella, U. B. (2003) · CRC Press eBooks · doi:10.1201/9780203912072-6 · Cited by 30
Nucleoside transport mechanisms in the pigmented rabbit conjunctiva.
Hosoya, K., Horibe, Y., Kim, K., & Lee, V. H. L. (1998) · PubMed · Cited by 29
Yang, J. J., Ann, D. K., Kannan, R., & Lee, V. H. L. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9267-7 · Cited by 28
Ion transport mechanisms in cultured bovine corneal endothelial cells
Jentsch, T. J., Keller, S. K., & Wiederholt, M. (1985) · Current Eye Research · doi:10.3109/02713688509025149 · Cited by 27
Biological Membranes and Barriers
Omidi, Y., & Gumbleton, M. (2015) · Taylor & Francis eBooks · doi:10.1081/e-ebpp-120052223 · Cited by 27
Self-citationJu, M., Mailhos, C., Bradley, J. M. B., Dowie, T., Ganley, M., Cook, G., Calias, P., Lange, N., Adamis, A. P., Shima, D. T., et al. (2008) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.07-0195 · Cited by 24
Lee, T. W.-Y., & Robinson, J. R. (2004) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/108076804772745464 · Cited by 22
Pece, A., Isola, V., Vadalà, M., & Calori, G. (2007) · Retina · doi:10.1097/01.iae.0000239253.78495.8c · Cited by 21
Ocular gene therapy trials due to report this year; Keeping an eye on clinical trials in 2008
Bainbridge, J. W., & Ali, R. R. (2008) · Gene Therapy · doi:10.1038/gt.2008.28 · Cited by 14
Expression of Monocarboxylate Transporter 1 in Oral and Ocular Canine Melanocytic Tumors
Shimoyama, Y., AKIHARA, Y., Kirat, D., Iwano, H., Hirayama, K., Kagawa, Y., Ohmachi, T., Matsuda, K., Okamoto, M., KADOSAWA, T., et al. (2007) · Veterinary Pathology · doi:10.1354/vp.44-4-449 · Cited by 11
Cited by
Gaudana, R., Ananthula, H. K., Parenky, A., & Mitra, A. K. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9183-3 · Cited by 1,406
“Both cell layers express tight junctional complexes and prevent the entry of solutes into the intraocular environment (6) such as the aqueous humor.”
BackgroundA comprehensive insight on ocular pharmacokinetics
Agrahari, V., Mandal, A., Agrahari, V., Trinh, H. M., Joseph, M., Ray, A., Hadji, H., Mitra, R., Pal, D., & Mitra, A. K. (2016) · Drug Delivery and Translational Research · doi:10.1007/s13346-016-0339-2 · Cited by 462
Nanotechnology-based strategies for treatment of ocular disease
Weng, Y., Liu, J., Jin, S., Guo, W., Liang, X., & Hu, Z. (2017) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.09.001 · Cited by 375
Chitosan-based nanostructures: A delivery platform for ocular therapeutics
de la Fuente, M., Raviña, M., Paolicelli, P., Sanchez, A., Seijo, B., & Alonso, M. J. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.026 · Cited by 354
Varela-Fernández, R., Díaz-Tomé, V., Luaces-Rodríguez, A., Conde-Penedo, A., García-Otero, X., Luzardo-Álvarez, A., Fernández-Ferreiro, A., & Otero-Espinar, F. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030269 · Cited by 354
Metadata
- Authors
- Barar, J., Javadzadeh, A. R., & Omidi, Y.
- Venue
- Expert Opinion on Drug Delivery
- Publisher
- Informa UK Limited
- Published
- 2008-05
- Volume
- 5
- Issue
- 5
- Pages
- 567-581
- ISSN
- 1742-5247 (ISSN-L)
- 1744-7593
- OpenAlex
- W2047399850
- Cited by
- 308
- References
- 88
- FWCI
- 6.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.